Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

University of British Columbia

1968, Vancouver, British Columbia, Canada

Medical School

Boston University School of Medicine

1978, Boston, MA

Internship

Beth Israel Deaconess Medical Center

1979, Boston, MA

Residency

Massachusetts Eye and Ear Infirmary

1982, Boston, MA

Fellowship

Boston Children's Hospital

1983, Boston, MA

Certifications

  • American Board of Ophthalmology (General)

Publications

  1. Evaluation of timed dexamethasone eye drops to prevent proliferative retinopathy of prematurity: a study protocol for a randomized intervention, multi-centre, double-blinded trial (DROPROP). BMC Pediatr. 2025 Apr 28; 25(1):332. View Abstract

  2. ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leakage. Angiogenesis. 2025 Apr 23; 28(2):24. View Abstract

  3. Choroidal Neovascularization Is Suppressed With Activation of TREM2 in Mononuclear Phagocytes-Brief Report. Arterioscler Thromb Vasc Biol. 2025 May; 45(5):769-777. View Abstract

  4. Visual and refractive outcomes in pediatric Marfan syndrome. J AAPOS. 2025 Apr; 29(2):104175. View Abstract

  5. Association between Early Postnatal Hydrocortisone and Retinopathy of Prematurity in Extremely Preterm Infants. Neonatology. 2025 Jan 21; 1-10. View Abstract

  6. Platelet characteristics in extremely preterm infants after fatty acid supplementation: a randomized controlled trial. Pediatr Res. 2024 Dec 19. View Abstract

  7. Increased risk of autism in extremely preterm children with a history of retinopathy of prematurity. Acta Paediatr. 2025 Jun; 114(6):1161-1168. View Abstract

  8. Therapeutic Effects of Taurine and Histidine Supplementation in Retinal Diseases. Life (Basel). 2024 Nov 29; 14(12). View Abstract

  9. Correction: Mitochondrial control of hypoxia-induced pathological retinal angiogenesis. Angiogenesis. 2024 Nov; 27(4):701-702. View Abstract

  10. Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity. Angiogenesis. 2024 Nov; 27(4):903-917. View Abstract

  11. Mitochondrial control of hypoxia-induced pathological retinal angiogenesis. Angiogenesis. 2024 Nov; 27(4):691-699. View Abstract

  12. Botulinum neurotoxin serotype A inhibited ocular angiogenesis through modulating glial activation via SOCS3. Angiogenesis. 2024 Nov; 27(4):753-764. View Abstract

  13. Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity. Res Sq. 2024 Jun 25. View Abstract

  14. ROP: 80 Years after Its Detection - Where Do We Stand and How Long Will We Continue to Laser? Neonatology. 2024; 121(5):608-615. View Abstract

  15. Therapeutic Effects of Anti-Inflammatory and Anti-Oxidant Nutritional Supplementation in Retinal Ischemic Diseases. Int J Mol Sci. 2024 May 18; 25(10). View Abstract

  16. Nutritional interventions to prevent retinopathy of prematurity. Pediatr Res. 2024 Sep; 96(4):905-911. View Abstract

  17. Arachidonic acid and docosahexaenoic acid levels correlate with the inflammation proteome in extremely preterm infants. Clin Nutr. 2024 May; 43(5):1162-1170. View Abstract

  18. Visual outcome at 2.5 years of age in ?-3 and ?-6 long-chain polyunsaturated fatty acid supplemented preterm infants: a follow-up of a randomized controlled trial. Lancet Reg Health Eur. 2023 Sep; 32:100696. View Abstract

  19. Prognostic Value of Parenteral Nutrition Duration on Risk of Retinopathy of Prematurity: Development and Validation of the Revised DIGIROP Clinical Decision Support Tool. JAMA Ophthalmol. 2023 08 01; 141(8):716-724. View Abstract

  20. In vivo noninvasive mitochondrial redox assessment of the optic nerve head to predict disease. PNAS Nexus. 2023 May; 2(5):pgad148. View Abstract

  21. Modification of serum fatty acids in preterm infants by parenteral lipids and enteral docosahexaenoic acid/arachidonic acid: A secondary analysis of the Mega Donna Mega trial. Clin Nutr. 2023 06; 42(6):962-971. View Abstract

  22. FGF21 via mitochondrial lipid oxidation promotes physiological vascularization in a mouse model of Phase I ROP. Angiogenesis. 2023 08; 26(3):409-421. View Abstract

  23. Therapeutic activation of endothelial sphingosine-1-phosphate receptor 1 by chaperone-bound S1P suppresses proliferative retinal neovascularization. EMBO Mol Med. 2023 05 08; 15(5):e16645. View Abstract

  24. Retinopathy of prematurity: Metabolic risk factors. Elife. 2022 11 24; 11. View Abstract

  25. Murine endothelial serine palmitoyltransferase 1 (SPTLC1) is required for vascular development and systemic sphingolipid homeostasis. Elife. 2022 Oct 05; 11. View Abstract

  26. Cytochrome P450 oxidase 2J inhibition suppresses choroidal neovascularization in mice. Metabolism. 2022 09; 134:155266. View Abstract

  27. National cohort of infants born before 24 gestational weeks showed increased survival rates but no improvement in neonatal morbidity. Acta Paediatr. 2022 08; 111(8):1515-1525. View Abstract

  28. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants. JAMA Ophthalmol. 2022 04 01; 140(4):337-344. View Abstract

  29. Omega-3/Omega-6 Long-Chain Fatty Acid Imbalance in Phase I Retinopathy of Prematurity. Nutrients. 2022 Mar 23; 14(7). View Abstract

  30. Neurodevelopmental disorders and somatic diagnoses in a national cohort of children born before 24 weeks of gestation. Acta Paediatr. 2022 06; 111(6):1167-1175. View Abstract

  31. Müller glial responses compensate for degenerating photoreceptors in retinitis pigmentosa. Exp Mol Med. 2021 11; 53(11):1748-1758. View Abstract

  32. Association of Docosahexaenoic Acid and Arachidonic Acid Serum Levels With Retinopathy of Prematurity in Preterm Infants. JAMA Netw Open. 2021 10 01; 4(10):e2128771. View Abstract

  33. Insulin-Like Growth Factor 1 in the Preterm Rabbit Pup: Characterization of Cerebrovascular Maturation following Administration of Recombinant Human Insulin-Like Growth Factor 1/Insulin-Like Growth Factor 1-Binding Protein 3. Dev Neurosci. 2021; 43(5):281-295. View Abstract

  34. Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity. Br J Ophthalmol. 2022 11; 106(11):1573-1580. View Abstract

  35. Sphingolipidomics of serum in extremely preterm infants: Association between low sphingosine-1-phosphate levels and severe retinopathy of prematurity. Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Jul; 1866(7):158939. View Abstract

  36. Cellular senescence in pathologic retinal angiogenesis. Trends Endocrinol Metab. 2021 07; 32(7):415-416. View Abstract

  37. Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr. 2021 04 01; 175(4):359-367. View Abstract

  38. Retinal glial remodeling by FGF21 preserves retinal function during photoreceptor degeneration. iScience. 2021 Apr 23; 24(4):102376. View Abstract

  39. Decreased Platelet Counts and Serum Levels of VEGF-A, PDGF-BB, and BDNF in Extremely Preterm Infants Developing Severe ROP. Neonatology. 2021; 118(1):18-27. View Abstract

  40. Fatty acid oxidation and photoreceptor metabolic needs. J Lipid Res. 2021; 62:100035. View Abstract

  41. Vitreous metabolomics profiling of proliferative diabetic retinopathy. Diabetologia. 2021 01; 64(1):70-82. View Abstract

  42. Notice of Withdrawal: Retinal Vasculature in Development and Diseases. Annu Rev Vis Sci. 2020 10 15; 0. View Abstract

  43. Randomized Control Trial of Postnatal rhIGF-1/rhIGFBP-3 Replacement in Preterm Infants: Post-hoc Analysis of Its Effect on Brain Injury. Front Pediatr. 2020; 8:517207. View Abstract

  44. An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis. J Vis Exp. 2020 08 06; (162). View Abstract

  45. Association between low fatty acid levels and platelet count in infants with Retinopathy of Prematurity. Acta Paediatr. 2020 12; 109(12):2547-2548. View Abstract

  46. Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data. Acta Ophthalmol. 2021 Mar; 99(2):201-206. View Abstract

  47. Free fatty acid receptor 4 activation protects against choroidal neovascularization in mice. Angiogenesis. 2020 08; 23(3):385-394. View Abstract

  48. Sphingosine 1-Phosphate Receptor Signaling Establishes AP-1 Gradients to Allow for Retinal Endothelial Cell Specialization. Dev Cell. 2020 03 23; 52(6):779-793.e7. View Abstract

  49. Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models. Int J Mol Sci. 2020 Feb 11; 21(4). View Abstract

  50. Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics. JAMA Ophthalmol. 2020 01 01; 138(1):21-29. View Abstract

  51. Pathophysiology of Diabetic Retinopathy: Contribution and Limitations of Laboratory Research. Ophthalmic Res. 2019; 62(4):196-202. View Abstract

  52. Leucocytosis is associated with retinopathy of prematurity in extremely preterm infants. Acta Paediatr. 2019 07; 108(7):1357-1358. View Abstract

  53. Tailored vs Static Oxygen Saturation Targets to Prevent Retinopathy of Prematurity. JAMA Ophthalmol. 2019 04 01; 137(4):423-424. View Abstract

  54. Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials. JAMA Ophthalmol. 2019 03 01; 137(3):305-311. View Abstract

  55. Review shows that donor milk does not promote the growth and development of preterm infants as well as maternal milk. Acta Paediatr. 2019 06; 108(6):998-1007. View Abstract

  56. Association of Somatic GNAQ Mutation With Capillary Malformations in a Case of Choroidal Hemangioma. JAMA Ophthalmol. 2019 01 01; 137(1):91-95. View Abstract

  57. rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial. J Pediatr. 2019 03; 206:56-65.e8. View Abstract

  58. Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity. Pediatr Res. 2019 08; 86(2):276-282. View Abstract

  59. Retinal Vasculature in Development and Diseases. Annu Rev Vis Sci. 2018 09 15; 4:101-122. View Abstract

  60. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. Ophthalmology. 2018 12; 125(12):1961-1966. View Abstract

  61. Influence of Human Milk and Parenteral Lipid Emulsions on Serum Fatty Acid Profiles in Extremely Preterm Infants. JPEN J Parenter Enteral Nutr. 2019 01; 43(1):152-161. View Abstract

  62. Relation of Retinopathy of Prematurity to Brain Volumes at Term Equivalent Age and Developmental Outcome at 2 Years of Corrected Age in Very Preterm Infants. Neonatology. 2018; 114(1):46-52. View Abstract

  63. Long-chain polyunsaturated fatty acids decline rapidly in milk from mothers delivering extremely preterm indicating the need for supplementation. Acta Paediatr. 2018 06; 107(6):1020-1027. View Abstract

  64. Association of Retinopathy of Prematurity With Low Levels of Arachidonic Acid: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 03 01; 136(3):271-277. View Abstract

  65. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr. 2018 03 01; 172(3):278-286. View Abstract

  66. Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice. Diabetes. 2018 05; 67(5):974-985. View Abstract

  67. PPARa is essential for retinal lipid metabolism and neuronal survival. BMC Biol. 2017 Nov 28; 15(1):113. View Abstract

  68. Increased postnatal concentrations of pro-inflammatory cytokines are associated with reduced IGF-I levels and retinopathy of prematurity. Growth Horm IGF Res. 2018 04; 39:19-24. View Abstract

  69. Implementing higher oxygen saturation targets reduced the impact of poor weight gain as a predictor for retinopathy of prematurity. Acta Paediatr. 2018 05; 107(5):767-773. View Abstract

  70. VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis. Nat Commun. 2017 08 29; 8(1):383. View Abstract

  71. Adiponectin Mediates Dietary Omega-3 Long-Chain Polyunsaturated Fatty Acid Protection Against Choroidal Neovascularization in Mice. Invest Ophthalmol Vis Sci. 2017 08 01; 58(10):3862-3870. View Abstract

  72. Cerebellar Exposure to Cell-Free Hemoglobin Following Preterm Intraventricular Hemorrhage: Causal in Cerebellar Damage? Transl Stroke Res. 2017 Jun 10. View Abstract

  73. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017 06 01; 135(6):654-656. View Abstract

  74. Effects of a lipid emulsion containing fish oil on polyunsaturated fatty acid profiles, growth and morbidities in extremely premature infants: A randomized controlled trial. Clin Nutr ESPEN. 2017 Aug; 20:17-23. View Abstract

  75. Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. J Exp Med. 2017 06 05; 214(6):1753-1767. View Abstract

  76. Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative. Ophthalmology. 2017 07; 124(7):926-934. View Abstract

  77. Sema3f Protects Against Subretinal Neovascularization In Vivo. EBioMedicine. 2017 Apr; 18:281-287. View Abstract

  78. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice. Cell Rep. 2017 02 14; 18(7):1606-1613. View Abstract

  79. IGF-1 as a Drug for Preterm Infants: A Step-Wise Clinical Development. Curr Pharm Des. 2017; 23(38):5964-5970. View Abstract

  80. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Nov; 13:201-211. View Abstract

  81. IGF-I in the clinics: Use in retinopathy of prematurity. Growth Horm IGF Res. 2016 Oct - Dec; 30-31:75-80. View Abstract

  82. IGF-1 in retinopathy of prematurity, a CNS neurovascular disease. Early Hum Dev. 2016 11; 102:13-19. View Abstract

  83. Aggressive Posterior Retinopathy of Prematurity Is Associated with Multiple Infectious Episodes and Thrombocytopenia. Neonatology. 2017; 111(1):79-85. View Abstract

  84. Role of Insulinlike Growth Factor 1 in Fetal Development and in the Early Postnatal Life of Premature Infants. Am J Perinatol. 2016 09; 33(11):1067-71. View Abstract

  85. Neurovascular cross talk in diabetic retinopathy: Pathophysiological roles and therapeutic implications. Am J Physiol Heart Circ Physiol. 2016 09 01; 311(3):H738-49. View Abstract

  86. Cytochrome P450 Oxidase 2C Inhibition Adds to ?-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization. Arterioscler Thromb Vasc Biol. 2016 09; 36(9):1919-27. View Abstract

  87. Corrigendum: Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1. Nat Med. 2016 06 07; 22(6):692. View Abstract

  88. Review: adiponectin in retinopathy. Biochim Biophys Acta. 2016 08; 1862(8):1392-400. View Abstract

  89. Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1. Nat Med. 2016 Apr; 22(4):439-45. View Abstract

  90. Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development. Acta Paediatr. 2016 Jun; 105(6):576-86. View Abstract

  91. The Eyes Absent Proteins in Developmental and Pathological Angiogenesis. Am J Pathol. 2016 Mar; 186(3):568-78. View Abstract

  92. SOCS3 in retinal neurons and glial cells suppresses VEGF signaling to prevent pathological neovascular growth. Sci Signal. 2015 Sep 22; 8(395):ra94. View Abstract

  93. Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity. Pediatr Res. 2016 Jan; 79(1-1):70-5. View Abstract

  94. Optimization of an Image-Guided Laser-Induced Choroidal Neovascularization Model in Mice. PLoS One. 2015; 10(7):e0132643. View Abstract

  95. Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis. 2015 Oct; 18(4):449-62. View Abstract

  96. Netrin-1 - DCC Signaling Systems and Age-Related Macular Degeneration. PLoS One. 2015; 10(5):e0125548. View Abstract

  97. Effect of Preterm Birth on Postnatal Apolipoprotein and Adipocytokine Profiles. Neonatology. 2015; 108(1):16-22. View Abstract

  98. Dietary ?-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin. Am J Clin Nutr. 2015 Apr; 101(4):879-88. View Abstract

  99. Low birth weight is a risk factor for severe retinopathy of prematurity depending on gestational age. PLoS One. 2014; 9(10):e109460. View Abstract

  100. Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come? Neonatology. 2014; 106(3):254-60. View Abstract

  101. Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration. Am J Ophthalmol. 2014 Nov; 158(5):1071-78. View Abstract

  102. Weight at first detection of retinopathy of prematurity predicts disease severity. Br J Ophthalmol. 2014 Nov; 98(11):1565-9. View Abstract

  103. Cytochrome P450 2C8 ?3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report. Arterioscler Thromb Vasc Biol. 2014 Mar; 34(3):581-6. View Abstract

  104. Sirtuin1 over-expression does not impact retinal vascular and neuronal degeneration in a mouse model of oxygen-induced retinopathy. PLoS One. 2014; 9(1):e85031. View Abstract

  105. WINROP identifies severe retinopathy of prematurity at an early stage in a nation-based cohort of extremely preterm infants. PLoS One. 2013; 8(9):e73256. View Abstract

  106. Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy. Angiogenesis. 2013 Oct; 16(4):985-92. View Abstract

  107. Choroid sprouting assay: an ex vivo model of microvascular angiogenesis. PLoS One. 2013; 8(7):e69552. View Abstract

  108. Retinopathy of prematurity. Lancet. 2013 Oct 26; 382(9902):1445-57. View Abstract

  109. The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment. Clin Perinatol. 2013 Jun; 40(2):201-14. View Abstract

  110. Semaphorin 3F forms an anti-angiogenic barrier in outer retina. FEBS Lett. 2013 Jun 05; 587(11):1650-5. View Abstract

  111. Altered cholesterol homeostasis in aged macrophages linked to neovascular macular degeneration. Cell Metab. 2013 Apr 02; 17(4):471-2. View Abstract

  112. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal Neonatal Med. 2013 Jun; 18(3):136-142. View Abstract

  113. DNA sequence variants in PPARGC1A, a gene encoding a coactivator of the ?-3 LCPUFA sensing PPAR-RXR transcription complex, are associated with NV AMD and AMD-associated loci in genes of complement and VEGF signaling pathways. PLoS One. 2013; 8(1):e53155. View Abstract

  114. Author response: Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? Invest Ophthalmol Vis Sci. 2012 Nov 19; 53(12):7728-9. View Abstract

  115. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res. 2013 Jan; 73(1):68-74. View Abstract

  116. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2012 Aug; 130(8):992-9. View Abstract

  117. LRP5 regulates development of lung microvessels and alveoli through the angiopoietin-Tie2 pathway. PLoS One. 2012; 7(7):e41596. View Abstract

  118. SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood. 2012 Oct 04; 120(14):2925-9. View Abstract

  119. Propranolol inhibition of ß-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2012 May 17; 53(6):2968-77. View Abstract

  120. Protective inflammasome activation in AMD. Nat Med. 2012 May 04; 18(5):658-60. View Abstract

  121. Retinal expression of Wnt-pathway mediated genes in low-density lipoprotein receptor-related protein 5 (Lrp5) knockout mice. PLoS One. 2012; 7(1):e30203. View Abstract

  122. Wnt signaling mediates pathological vascular growth in proliferative retinopathy. Circulation. 2011 Oct 25; 124(17):1871-81. View Abstract

  123. Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proc Natl Acad Sci U S A. 2011 Sep 13; 108(37):15231-6. View Abstract

  124. Ghrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1a. Invest Ophthalmol Vis Sci. 2011 Jul 23; 52(8):5376-86. View Abstract

  125. Maternal and neonatal factors associated with poor early weight gain and later retinopathy of prematurity. Acta Paediatr. 2011 Dec; 100(12):1528-33. View Abstract

  126. Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice. Invest Ophthalmol Vis Sci. 2011 Apr; 52(5):2809-16. View Abstract

  127. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr. 2011 Apr; 23(2):173-8. View Abstract

  128. Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. Br J Ophthalmol. 2011 Nov; 95(11):1496-501. View Abstract

  129. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood. 2011 Jun 02; 117(22):6024-35. View Abstract

  130. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ?-3 polyunsaturated fatty acids. Sci Transl Med. 2011 Feb 09; 3(69):69ra12. View Abstract

  131. Analysis of candidate genes for macular telangiectasia type 2. Mol Vis. 2010 Dec 14; 16:2718-26. View Abstract

  132. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010 Dec; 177(6):2715-23. View Abstract

  133. Predicting proliferative retinopathy in a Brazilian population of preterm infants with the screening algorithm WINROP. Arch Ophthalmol. 2010 Nov; 128(11):1432-6. View Abstract

  134. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina. 2010 Oct; 30(9):1524-9. View Abstract

  135. Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion. Biochim Biophys Acta. 2011 Apr; 1812(4):549-57. View Abstract

  136. Moderate GSK-3ß inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy. Angiogenesis. 2010 Sep; 13(3):269-77. View Abstract

  137. An eye for discovery. J Clin Invest. 2010 Sep; 120(9):3008-11. View Abstract

  138. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci. 2010 Jul 21; 30(29):9695-707. View Abstract

  139. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res. 2010 Aug 20; 107(4):495-500. View Abstract

  140. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010 Jun; 51(6):2813-26. View Abstract

  141. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010 Jun; 125(6):e1483-92. View Abstract

  142. Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol. 2010 Apr; 128(4):443-7. View Abstract

  143. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009; 4(11):1565-73. View Abstract

  144. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol. 2009 May; 127(5):622-7. View Abstract

  145. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res. 2009 May; 65(5):574-9. View Abstract

  146. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009 Apr; 123(4):e638-45. View Abstract

  147. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol. 2009 Mar-Apr; 24(2):77-81. View Abstract

  148. Emerging treatments for retinopathy of prematurity. Semin Ophthalmol. 2009 Mar-Apr; 24(2):82-6. View Abstract

  149. A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature. 2009 Feb 26; 457(7233):1103-8. View Abstract

  150. Quantification and localization of the IGF/insulin system expression in retinal blood vessels and neurons during oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2009 Apr; 50(4):1831-7. View Abstract

  151. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009 Mar; 50(3):1329-35. View Abstract

  152. Use of Bayesian networks to probabilistically model and improve the likelihood of validation of microarray findings by RT-PCR. J Biomed Inform. 2009 Apr; 42(2):287-95. View Abstract

  153. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008 Dec; 49(12):5177-82. View Abstract

  154. A double-edged sword: erythropoietin eyed in retinopathy of prematurity. J AAPOS. 2008 Jun; 12(3):221-2. View Abstract

  155. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008 Feb; 118(2):526-33. View Abstract

  156. Overstaying their welcome: defective CX3CR1 microglia eyed in macular degeneration. J Clin Invest. 2007 Oct; 117(10):2758-62. View Abstract

  157. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007 Jul; 13(7):868-873. View Abstract

  158. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A. 2007 Jun 19; 104(25):10589-94. View Abstract

  159. Retinopathy of prematurity. Angiogenesis. 2007; 10(2):133-40. View Abstract

  160. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006 Dec; 124(12):1711-8. View Abstract

  161. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics. 2006 Jun; 117(6):1930-8. View Abstract

  162. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis. 2006 May 23; 12:532-80. View Abstract

  163. A radically twisted lipid regulates vascular death. Nat Med. 2005 Dec; 11(12):1275-6. View Abstract

  164. Quantitative multi-gene transcriptional profiling using real-time PCR with a master template. Exp Mol Pathol. 2005 Aug; 79(1):14-22. View Abstract

  165. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci. 2005 Aug; 46(8):2736-47. View Abstract

  166. IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate. 2005; 88(3):237-44. View Abstract

  167. Periorbital lymphatic malformation: clinical course and management in 42 patients. Plast Reconstr Surg. 2005 Jan; 115(1):22-30. View Abstract

  168. Mechanical stretch is a highly selective regulator of gene expression in human bladder smooth muscle cells. Physiol Genomics. 2004 Dec 15; 20(1):36-44. View Abstract

  169. Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa. J Clin Invest. 2004 Sep; 114(6):755-7. View Abstract

  170. Can we restore aspects of the in utero environment in premature infants to prevent disease? Pediatrics. 2004 Aug; 114(2):491. View Abstract

  171. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004 Jun; 14 Suppl A:S140-4. View Abstract

  172. Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci U S A. 2003 Dec 23; 100(26):15859-64. View Abstract

  173. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003 Dec; 8(6):469-73. View Abstract

  174. Adipose tissue growth and regression are regulated by angiopoietin-1. Biochem Biophys Res Commun. 2003 Nov 21; 311(3):563-71. View Abstract

  175. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003 Nov; 112(5):1016-20. View Abstract

  176. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest. 2003 Jul; 112(1):50-7. View Abstract

  177. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer. 2002 Sep 20; 101(3):224-34. View Abstract

  178. Stem cells go for the eyes. Nat Med. 2002 Sep; 8(9):932-4. View Abstract

  179. Molecular profiling of angiogenesis markers. Am J Pathol. 2002 Jul; 161(1):35-41. View Abstract

  180. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab. 2002 Jul; 87(7):3413-6. View Abstract

  181. RP-forme fruste. J Perinatol. 2002 Apr-May; 22(3):257; author reply 257-8. View Abstract

  182. Pathogenesis of retinopathy of prematurity. Acta Paediatr Suppl. 2002; 91(437):26-8. View Abstract

  183. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001 May 08; 98(10):5804-8. View Abstract

  184. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J. 2001 May; 15(7):1215-7. View Abstract

  185. Heat shock protein 90 in retinal ganglion cells: association with axonally transported proteins. Vis Neurosci. 2001 May-Jun; 18(3):429-36. View Abstract

  186. Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials. Urology. 2001 Apr; 57(4 Suppl 1):143-7. View Abstract

  187. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999 Dec; 5(12):1390-5. View Abstract

  188. Oligonucleotide-based inhibition of embryonic gene expression. Nat Biotechnol. 1999 Dec; 17(12):1184-7. View Abstract

  189. Progressive juvenile onset punctate cataracts caused by mutation of the gamma D crystalline gene. Proc Natl Acad Sci USA. 1999; 96(3):1008-1012.

  190. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997 Sep; 46(9):1473-80. View Abstract

  191. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997 Jun 13; 276(5319):1706-9. View Abstract

  192. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS. 1997 Jun; 1(2):105-10. View Abstract

  193. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996 Oct; 114(10):1219-28. View Abstract

  194. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A. 1996 May 14; 93(10):4851-6. View Abstract

  195. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995 Nov 07; 92(23):10457-61. View Abstract

  196. Enamel hypoplasia, bilateral cataracts, and aqueductal stenosis: a new syndrome? Am J Med Genet. 1995 Sep 25; 58(4):371-3. View Abstract

  197. Conjunctival biopsy in patients with Kawasaki disease. Pediatr Pathol Lab Med. 1995 Jul-Aug; 15(4):547-53. View Abstract

  198. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995 Jan 31; 92(3):905-9. View Abstract

  199. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994 Jan; 35(1):101-11. View Abstract

  200. Effect of light on oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994 Jan; 35(1):112-9. View Abstract

  201. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res. 1993 Sep; 46(2):135-42. View Abstract

  202. Alterations in endothelial superoxide dismutase levels as a function of growth state in vitro. Invest Ophthalmol Vis Sci. 1992 Jan; 33(1):36-41. View Abstract

  203. Kawasaki Syndrome in the Eye. Pediatric Infectious Disease Journal. 1989; 8:116-118.

  204. Characterization of vascular development in the mouse retina. Microvasc Res. 1988 Nov; 36(3):275-90. View Abstract

  205. Ophthalmic evaluation of survivors of acute lymphoblastic leukemia. Ophthalmology. 1988 Feb; 95(2):151-5. View Abstract

  206. Neuroanatomy of the human visual system: part II- Retinal projections to the superior colliculus and pulvinar. Neuro-ophthalmology. 1986; 6(6):362-370.

  207. A retinohypothalamic pathway in man: light mediation of circadian rhythms. Brain Res. 1984 Jun 08; 302(2):371-7. View Abstract

  208. Paraphenylenediamine: a new method for tracing human visual pathways. J Neuropathol Exp Neurol. 1983 Mar; 42(2):200-6. View Abstract

  209. Direct demonstration of transsynaptic degeneration in the human visual system. Journal of Neurology Neurosurgery Psychiatry. 1982; 45:143.

  210. Alpha-secondary tritium isotope effects in the aqueous hydrolysis of glycopyranosides of N-acetyl-beta-D-glucosamine. Arch Biochem Biophys. 1973 Nov; 159(1):505-11. View Abstract

  211. Mechanism for lysozyme-catalyzed hydrolysis. J Am Chem Soc. 1973 Oct 31; 95(22):7497-7500. View Abstract
BESbswy
BESbswy